Tejal Somvanshi
Amanda Peet was diagnosed with Stage 1 breast cancer after noticing a skin change she described as “weird” — not a lump, not pain, just an unusual sensation. The symptom she paid attention to is one that standard breast cancer awareness campaigns rarely describe in detail, and her diagnosis sheds light on a cancer type that can be harder to detect on standard mammograms.
Peet disclosed her diagnosis first in an essay for The New Yorker and expanded on it in an interview on NBC’s Today show. Her first noticeable sign was a subtle skin change, which prompted her to request an MRI. A later routine ultrasound led to a biopsy confirming Stage 1 Invasive Lobular Carcinoma. During the MRI workup, a second suspicious area in the same breast was identified — an area that was subsequently biopsied and found to be benign, sparing her a mastectomy. She underwent a lumpectomy and radiation therapy without requiring chemotherapy. Invasive Lobular Carcinoma accounts for approximately 15% of all breast cancers, according to the Lobular Breast Cancer Alliance.
Peet’s experience points to a real screening gap for women with dense breast tissue or unremarkable mammogram histories. Invasive lobular carcinoma grows in thin, single-file sheets of cells through surrounding breast tissue rather than forming a distinct mass — which is why it mimics normal glandular structure on a standard 2D mammogram and can appear clear even when disease is present. If you notice a persistent breast change despite a recent normal mammogram, discuss it with a clinician rather than assuming the imaging result rules out cancer. Whether supplemental imaging is appropriate depends on the specific finding, breast density, and individual risk.
Why Lobular Breast Cancer Is Harder to Find on a Standard Mammogram Standard 2D mammograms detect cancer primarily by identifying dense nodules or calcification clusters that stand out against surrounding fatty tissue. Invasive lobular carcinoma grows differently: cells spread in diffuse lines through normal breast tissue rather than forming the compact circular mass that X-ray imaging is most sensitive to. The result is that ILC can appear normal or nearly normal on a standard screening mammogram even with meaningful disease present.
This is a limitation of what 2D X-ray imaging can detect against specific cellular growth patterns — not a failure of the technology for the cancers it was designed to find. Three-dimensional tomosynthesis, contrast-enhanced mammography, and MRI can offer improved sensitivity in some cases of lobular cancer, particularly in women with dense breast tissue, though performance varies by clinical context.
Women with dense breasts — about half of women aged 40 and older — receive density notifications in states with reporting laws, and supplemental screening options vary by insurance coverage and location. Peet’s case adds a personal account to what the Lobular Breast Cancer Alliance has long documented in its clinical statistics: ILC can be harder to detect on mammography and may therefore be diagnosed at a later stage in some patients.
Peet’s experience is one individual case, not a clinical guideline. The right screening approach for any person depends on their risk factors, breast density classification, and personal medical history — a conversation for their primary care provider or gynecologist.
Breast Cancer Awareness Month runs through October, making this a relevant moment to review your screening history. For information on dense breast tissue and mammography, the National Cancer Institute’s dense breasts resource provides current clinical context. For background on what ILC is and how it differs from other breast cancer types, the Lobular Breast Cancer Alliance covers the clinical distinction in detail.
Peet said in her October 1, 2026 TODAY interview that she was feeling well after receiving her first clear scan in January. Check back for any updates from Lobular Breast Cancer Alliance research on targeted ILC therapies.
